Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAFV600E and KIT immunoexpression in early-stage melanoma.

Anais brasileiros de dermatologia - 1 Jan 2019

Germano Andressa, Cardili Leonardo, Carapeto Fernando Cintra Lopes, Landman Gilles

Abstract excerpt

Melanoma is widely known as the most lethal skin cancer. Specific tumor-related mortality can be significantly reduced if diagnosis and treatment are properly performed during initial phases of the disease. The current search for biomarkers in early-stage melanomas is a high-priority challenge for physicians and researchers. We aimed to assess the immunoexpression of BRAFV600E and KIT in a case series consisting...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease Progression
Share to Immunohistochemistry
Share to Melanoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mitogen-Activated Protein Kinases

Share to Neoplasm Staging

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins c-kit

Share to Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 31644622
DOI: 10.1590/abd1806-4841.20198349
PMCID: PMC7007021

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAFV600E and KIT immunoexpression in early-stage melanoma.PMID 31644622Read ↗

Use of BRAF immunohistochemistry as a screening test in detecting BRAFV600E mutation in melanomas.Semantic proximity Read ↗

Melanoma: diagnosis, staging, and treatment. Consensus group recommendations.Semantic proximity Read ↗

BRAFp.V600E, p.V600K, and p.V600R Mutations in Malignant Melanoma: Do They Also Differ in Immunohistochemical Assessment and Clinical Features?Semantic proximity Read ↗

Molecular histology on the diagnostic cutting edge between malignant melanomas and cutaneous melanocytomas (Review).Semantic proximity Read ↗

[Advancements in the diagnosis of melanoma].Semantic proximity Read ↗

Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature.Semantic proximity Read ↗

Immune-phenotypical markers for the differential diagnosis of melanocytic lesions.Semantic proximity Read ↗

Biomarkers in melanoma: predisposition, screening and diagnosis.Semantic proximity Read ↗

KIT and Melanoma: Biological Insights and Clinical Implications.Semantic proximity Read ↗

Immunohistochemistry as a quick screening method for clinical detection of BRAF(V600E) mutation in melanoma patients.Semantic proximity Read ↗

BRAF V600E Expression in Primary Melanoma and Its Association With Death: A Population-Based, Retrospective, Cross-Sectional Study.Semantic proximity Read ↗

BRAF V600K vs. BRAF V600E: a comparison of clinical and dermoscopic characteristics and response to immunotherapies and targeted therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.